Psychedelics and Psychedelic-Assisted Psychotherapy
The DOI matches its Crossref record; 121 of the 121 references it cites were found in a registry or an index.
Abstract
Objective: The authors provide an evidenced-based summary of the literature on the clinical application of psychedelic drugs in psychiatric disorders. Methods: Searches of PubMed and PsycINFO via Ovid were conducted for articles in English, in peer-reviewed journals, reporting on “psilocybin,” “lysergic acid diethylamide,” “LSD,” “ayahuasca,” “3,4-methylenedioxymethamphetamine,” and “MDMA,” in human subjects, published between 2007 and July 1, 2019. A total of 1,603 articles were identified and screened. Articles that did not contain the terms “clinical trial,” “therapy,” or “imaging” in the title or abstract were filtered out. The 161 remaining articles were reviewed by two or more authors. The authors identified 14 articles reporting on well-designed clinical trials investigating the efficacy of lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and ayahuasca for the treatment of mood and anxiety disorders, trauma and stress-related disorders, and substance-related and addictive disorders as well as in end-of-life care. Results: The most significant database exists for MDMA and psilocybin, which have been designated by the U.S. Food and Drug Administration (FDA) as “breakthrough therapies” for posttraumatic stress disorder (PTSD) and treatment-resistant depression, respectively. The research on LSD and ayahuasca is observational, but available evidence suggests that these agents may have therapeutic effects in specific psychiatric disorders. Conclusions: Randomized clinical trials support the efficacy of MDMA in the treatment of PTSD and psilocybin in the treatment of depression and cancer-related anxiety. The research to support the use of LSD and ayahuasca in the treatment of psychiatric disorders is preliminary, although promising. Overall, the database is insufficient for FDA approval of any psychedelic compound for routine clinical use in psychiatric disorders at this time, but continued research on the efficacy of psychedelics for the treatment of psychiatric disorders is warranted.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, comorbid conditions such as suicidality and substance use disorders further complicate research efforts (13, 18, 20, 21).”
From Psychoanalytically informed MDMA-assisted therapy for pathological narcissism: a novel theoretical approach (2025) · cites this paper as [21]
In the citing paper
“Ketamine has also been considered for the treatment of PTSD, although information on this matter is still lacking (Krediet et al., 2020; Reiff et al., 2020).”
From Virtual reality and psychedelics for the treatment of psychiatric disease: A systematic literature review (2020) · doi:10.36131/cnfioritieditore20200606 · cites this paper as Reiff et al., 2020
In the citing paper
“Psychedelics such as psilocybin and lysergic acid diethylamide (LSD) are also novel therapeutics for MDD that show promise in clinical trials [124-126].”
From Beyond the serotonin deficit hypothesis: Communicating a neuroplasticity framework of major depressive disorder (2024) · cites this paper as [126]
Citations
Cites
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · cited 1×
“Ketamine NMDA antagonist Deficits in vigilance, verbal fluency, delayed recall, and tests of frontal lobe function (121) Derealization, depersonalization (8, 120, 121, 124); illusions in all sensory domains and perceptual alterations (121) Amotivation, emotional dulling, hostility (121); anxiety (121, 123) Improved mo…”
BackgroundGriffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Journal of Transpersonal Psychology
(1977) · Journal of Humanistic Psychology · doi:10.1177/002216787701700308 · Cited by 1,732
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 4×
“The mean change in HAM-D score 21 days after drug administration was 211.4. a AASE=Alcohol Abstinence Self-Efficacy Scale; BDI=Beck Depression Inventory; CAPS=Clinician-Administered PTSD Scale; LSD=lysergic acid diethylamide; DMT=N,N-dimethyltryptamine; HADS=Hospital Anxiety and Depression Scale; HAM-A=Hamilton Anxiet…”
BackgroundMethodInfluentialDrug harms in the UK: a multicriteria decision analysis
Nutt, D. J., King, L. A., & Phillips, L. D. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61462-6 · Cited by 1,681
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · cited 3×
“(23) conducted an openlabel pilot study evaluating the feasibility and efficacy of”
BackgroundCarhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00020 · Cited by 1,252
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206 · cited 2×
“(28) Randomized doubleblind placebo Cancer-related anxiety and depression 12 0.”
BackgroundNeural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151
Pilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914 · cited 6×
“Some scales, however, such as the MEQ-30, have been validated in experimental studies with controlled doses of psilocybin (32), although even the MEQ-30 was validated using a narrow range of drug doses and was restricted to one hallucinogenic compound.”
BackgroundInfluentialNeural correlates of the LSD experience revealed by multimodal neuroimaging
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, W., Murphy, K., Tagliazucchi, E., Schenberg, E. E., Nest, T., Orban, C., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518377113 · Cited by 859 · cited 1×
“, sense of self ) are correlatedwith decreased connectivity between the parahippocampus and retrosplenial cortex within the default mode network (125).”
BackgroundSafety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder
Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1110 · Cited by 789
Gasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., & Brenneisen, R. (2014) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0000000000000113 · Cited by 750 · cited 3×
“study mentioned (48) above was associated with worsening anxiety in people with comorbid medical illness.”
BackgroundInfluentialThe neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Vollenweider, F. X., & Kometer, M. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2884 · Cited by 723
Long-term follow-up of psilocybin-facilitated smoking cessation
Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2016.1170135 · Cited by 696
Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., & Doblin, R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110378371 · Cited by 674
Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin
Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115609019 · Cited by 637
Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.
Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., & The APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040465 · Cited by 598
Self-citationA Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders
Sanacora, G., Frye, M. A., McDonald, W., Mathew, S. J., Turner, M. S., Schatzberg, A. F., Summergrad, P., Nemeroff, C. B., & for the American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.0080 · Cited by 576
Self-citationCarbonaro, T. M., Bradstreet, M. P., Barrett, F. S., MacLean, K. A., Jesse, R., Johnson, M. W., & Griffiths, R. R. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116662634 · Cited by 553
Studerus, E., Kometer, M., Hasler, F., & Vollenweider, F. X. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110382466 · Cited by 532 · cited 1×
“In an analysis of 110 healthy study volunteers from 227 psilocybin administrations, researchers found no evidence of hallucinogen persisting perception disorder, prolonged psychosis, or other long-term impairment of functioning in any subjects (37).”
BackgroundGriffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., Jesse, R., MacLean, K. A., Barrett, F. S., Cosimano, M. P., & Klinedinst, M. A. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881117731279 · Cited by 520 · cited 3×
“mations that lead to dramatic or “quantum” changes in a person’s sense of self and behavior (34).”
BackgroundAttenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism
Williams, N. R., Heifets, B. D., Blasey, C., Sudheimer, K., Pannu, J., Pankow, H., Hawkins, J., Birnbaum, J., Lyons, D. M., Rodriguez, C. I., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18020138 · Cited by 519
Johnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.010 · Cited by 506 · cited 2×
“Psilocybin is actively metabolized to psilocin, a serotonin transporter inhibitor and 5-HT2A receptor partial agonist with ,40% activation efficacy; it also binds to the 5-HT2C, 5-HT1A, and 5-HT1B receptors, with binding affinities in descending order (11, 12).”
BackgroundOsório, F. D. L., Sanches, R. F., Macedo, L. R., dos Santos, R. G., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A., & Hallak, J. E. (2015) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2014-1496 · Cited by 488
Sanches, R. F., de Lima Osório, F., dos Santos, R. G., Macedo, L. R. H., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000436 · Cited by 466
The pharmacology of psilocybin
Passie, T., Seifert, J., Schneider, U., & Emrich, H. M. (2002) · Addiction Biology · doi:10.1080/1355621021000005937 · Cited by 465
Plants of the Gods: Their Sacred, Healing and Hallucinogenic Powers
Hofmann, A., & Schultes, R. E. (1992) · Medical Entomology and Zoology · Cited by 463
The pharmacology of lysergic acid diethylamide: A review
Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M., & Hintzen, A. (2008) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00059.x · Cited by 455
Mithoefer, M. C., Mithoefer, A. T., Feduccia, A. A., Jerome, L., Wagner, M., Wymer, J., Holland, J., Hamilton, S., Yazar-Klosinski, B., Emerson, A., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30135-4 · Cited by 439
Grunebaum, M. F., Galfalvy, H. C., Choo, T.-H., Keilp, J. G., Moitra, V. K., Parris, M. S., Marver, J. E., Burke, A. K., Milak, M. S., Sublette, M. E., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17060647 · Cited by 431
Serotonin research: contributions to understanding psychoses
GEYER, M., & VOLLENWEIDER, F. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.06.006 · Cited by 427
Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects
Schmid, Y., Enzler, F., Gasser, P., Grouzmann, E., Preller, K. H., Vollenweider, F. X., Brenneisen, R., Müller, F., Borgwardt, S., & Liechti, M. E. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.11.015 · Cited by 411
MacLean, K. A., Leoutsakos, J. S., Johnson, M. W., & Griffiths, R. R. (2012) · Journal for the Scientific Study of Religion · doi:10.1111/j.1468-5906.2012.01685.x · Cited by 405
Preller, K. H., Herdener, M., Pokorny, T., Planzer, A., Kraehenmann, R., Stämpfli, P., Liechti, M. E., Seifritz, E., & Vollenweider, F. X. (2017) · Current Biology · doi:10.1016/j.cub.2016.12.030 · Cited by 402
Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens
Rickli, A., Moning, O. D., Hoener, M. C., & Liechti, M. E. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.05.001 · Cited by 379
Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., Martin, S. F., Yazar-Klosinski, B., Michel, Y., Brewerton, T. D., & Doblin, R. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881112456611 · Cited by 376
Johnson, M. W., Griffiths, R. R., Hendricks, P. S., & Henningfield, J. E. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.05.012 · Cited by 354 · cited 2×
“procedure based on research evidence (143).”
BackgroundRecent advances in the neuropsychopharmacology of serotonergic hallucinogens
Halberstadt, A. L. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.07.016 · Cited by 312
Setola, V., Hufeisen, S. J., Grande-Allen, K. J., Vesely, I., Glennon, R. A., Blough, B., Rothman, R. B., & Roth, B. L. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.6.1223 · Cited by 304
Riba, J., Rodríguez-Fornells, A., Urbano, G., Morte, A., Antonijoan, R., Montero, M., Callaway, J. C., & Barbanoj, M. J. (2001) · Psychopharmacology · doi:10.1007/s002130000606 · Cited by 303
Psychedelics not linked to mental health problems or suicidal behavior: A population study
Johansen, P.-Ø., & Krebs, T. S. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114568039 · Cited by 302
Psychedelics and the Human Receptorome
Ray, T. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009019 · Cited by 301
The paradoxical psychological effects of lysergic acid diethylamide LSD
Carhart-Harris, R. L., Kaelen, M., Bolstridge, M., Williams, T. M., Williams, L. T., Underwood, R., Feilding, A., & Nutt, D. J. (2016) · Psychological Medicine · doi:10.1017/s0033291715002901 · Cited by 293 · cited 1×
“LSD, psilocybin, and ayahuasca (DMT) Serotonin 5-HT2A and 5-HT2C receptor agonist Increased cognitive flexibility (53), creative thinking (51), and insightfulness (52); distractibility and disorganized behavior (49, 51, 53, 62) Changes in visual perception (51, 53); mystical experiences (6, 12, 34, 52); paranoia (53);…”
BackgroundPhenomenology, Structure, and Dynamic of Psychedelic States
Preller, K. H., & Vollenweider, F. X. (2016) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2016_459 · Cited by 282
Neuropsychological mechanism underlying antidepressant effect: a systematic meta-analysis
Ma, Y. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.24 · Cited by 270
LSD Acutely Impairs Fear Recognition and Enhances Emotional Empathy and Sociality
Dolder, P. C., Schmid, Y., Müller, F., Borgwardt, S., & Liechti, M. E. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.82 · Cited by 247
Dumont, G. J. H., Sweep, F. C. G. J., van der Steen, R., Hermsen, R., Donders, A. R. T., Touw, D. J., van Gerven, J. M. A., Buitelaar, J. K., & Verkes, R. J. (2009) · Social Neuroscience · doi:10.1080/17470910802649470 · Cited by 238
Evidence‐based treatment of depression in patients with cancer
Li, M., Fitzgerald, P., & Rodin, G. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.7372 · Cited by 236 · cited 1×
“Mood and adjustment disorders comorbid with cancer diagnoses are debilitating and are associated with poor clinical outcomes (27).”
BackgroundModern clinical research on LSD
Liechti, M. E. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.86 · Cited by 236
Camí, J., Farré, M., Mas, M., Roset, P. N., Poudevida, S., Mas, A., San, L., & de la Torre, R. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200008000-00010 · Cited by 234 · cited 1×
“MDMA Serotonin 5-HT2A agonist; mixed serotonin, norepinephrine, and dopamine reuptake inhibition and release Deficits in spatial memory (111); mild impairment on psychomotor tasks (92) Changes in body perception, slight visual and auditory alterations, no hallucinations (92) Distrust and hostility (103); anxiety (93,…”
BackgroundThe role of ketamine in treatment-resistant depression: A systematic review
Serafini, G., Howland, R., Rovedi, F., Girardi, P., & Amore, M. (2014) · Current Neuropharmacology · doi:10.2174/1570159x12666140619204251 · Cited by 234
Long-lasting subjective effects of LSD in normal subjects.
Schmid, Y., & Liechti, M. E. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4733-3 · Cited by 232
Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans
Harris, D. S., Baggott, M., Mendelson, J. H., Mendelson, J. E., & Jones, R. T. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1131-1 · Cited by 229
Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance
Dinis-Oliveira, R. J. (2017) · Drug Metabolism Reviews · doi:10.1080/03602532.2016.1278228 · Cited by 224
Dore, J., Turnipseed, B., Dwyer, S., Turnipseed, A., Andries, J., Ascani, G., Monnette, C., Huidekoper, A., Strauss, N., & Wolfson, P. (2019) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1587556 · Cited by 217
Effects of MDMA on sociability and neural response to social threat and social reward
Bedi, G., Phan, K. L., Angstadt, M., & de Wit, H. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1635-z · Cited by 206
Clinical applications of hallucinogens: a review
Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000084 · Cited by 201 · cited 6×
“, psychedelic-assisted psychotherapy) and that expectations and the participants’ prior drug experiences are important variables in the response to psychedelic-assisted therapy (6).”
BackgroundMethodInfluentialAlterations of consciousness and mystical-type experiences after acute LSD in humans
Liechti, M. E., Dolder, P. C., & Schmid, Y. (2017) · Psychopharmacology · doi:10.1007/s00213-016-4453-0 · Cited by 198
Vollenweider, F. X., Csomor, P. A., Knappe, B., Geyer, M. A., & Quednow, B. B. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301324 · Cited by 190
Garcia-Romeu, A., & Richards, W. A. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1486289 · Cited by 189
The subjective effects of MDMA and mCPP in moderate MDMA users
Tancer, M. E., & Johanson, C.-E. (2001) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(01)00146-6 · Cited by 180
Grob, C. S., Poland, R. E., Chang, L., & Ernst, T. (1995) · Behavioural Brain Research · doi:10.1016/0166-4328(96)00078-2 · Cited by 175
Bershad, A. K., Schepers, S. T., Bremmer, M. P., Lee, R., & de Wit, H. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.05.019 · Cited by 175
Co-Occurring Psychotic and Addictive Disorders: Neurobiology and Diagnosis
Ross, S., & Peselow, E. (2012) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e318261e193 · Cited by 170
Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies
dos Santos, R. G., Bouso, J. C., & Hallak, J. E. C. (2017) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316689030 · Cited by 168
Kamilar-Britt, P., & Bedi, G. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.08.016 · Cited by 163
Pharmahuasca: Human Pharmacology of Oral DMT Plus Harmine
Ott, J. (1999) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1999.10471741 · Cited by 163
d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology
Gregorio, D. D., Comai, S., Posa, L., & Gobbi, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111953 · Cited by 153
Increased thalamic resting‐state connectivity as a core driver of LSD‐induced hallucinations
Müller, F., Lenz, C., Dolder, P. C., Lang, U. E., Schmidt, A., Liechti, M. E., & Borgwardt, S. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12818 · Cited by 151
Hysek, C. M., Simmler, L. D., Schillinger, N., Meyer, N., Schmid, Y., Donzelli, M., Grouzmann, E., & Liechti, M. E. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001132 · Cited by 145
MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults
Danforth, A. L., Struble, C. M., Yazar‐Klosinski, B., & Grob, C. S. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.03.011 · Cited by 140
The Psychedelic Explorer's Guide: Safe, Therapeutic, and Sacred Journeys
Fadiman, J. (2011) · Cited by 138
Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers
Johnson, M. W., Sewell, R. A., & Griffiths, R. R. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.10.029 · Cited by 137
Serotonergic Hallucinogen-Induced Visual Perceptual Alterations
Kometer, M., & Vollenweider, F. X. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_461 · Cited by 137
Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects
Müller, F., Lenz, C., Dolder, P. C., Harder, S., Schmid, Y., Lang, U. E., Liechti, M. E., & Borgwardt, S. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.54 · Cited by 136
LSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation
Krähenmann, R., Pokorný, D., Aicher, H., Preller, K. H., Pokorny, T., Bosch, O. G., Seifritz, E., & Vollenweider, F. X. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00814 · Cited by 126
dos Santos, R. G., Balthazar, F. M., Bouso, J. C., & Hallak, J. E. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116652578 · Cited by 125
Therapeutic infusions of ketamine: do the psychoactive effects matter?
Dakwar, E., Anerella, C., Hart, C. L., Levin, F. R., Mathew, S. J., & Nunes, E. V. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2013.12.019 · Cited by 123
Report on psychoactive drug use among adolescents using ayahuasca within a religious context.
Doering-Silveira, E., Grob, C. S., de Rios, M. D., Lopez, E., Alonso, L. K., Tacla, C., & Da Silveira, D. X. (2005) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2005.10399794 · Cited by 122
The Antipodes of the Mind: Charting the Phenomenology of the Ayahuasca Experience
Roberts, T. B. (2003) · Anthropology of Consciousness · doi:10.1525/ac.2003.14.1.75 · Cited by 120
Nielson, E. M., & Guss, J. R. (2018) · Journal of Psychedelic Studies · doi:10.1556/2054.2018.009 · Cited by 118
Behavioral Neurobiology of Psychedelic Drugs
(2018) · Current topics in behavioral neurosciences · doi:10.1007/978-3-662-55880-5 · Cited by 118
The early use of MDMA (‘Ecstasy') in Psychotherapy (1977–1985)
Passie, T. (2018) · Drug Science Policy and Law · doi:10.1177/2050324518767442 · Cited by 116
EXPERIMENTAL SCHIZOPHRENIA-LIKE SYMPTOMS
Rinkel, M., Deshon, H. J., Hyde, R. W., & Solomon, H. C. (1952) · American Journal of Psychiatry · doi:10.1176/ajp.108.8.572 · Cited by 114
Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD)
Nichols, D. E. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00043 · Cited by 109
Young, M. B., Norrholm, S. D., Khoury, L. M., Jovanovic, T., Rauch, S. A. M., Reiff, C. M., Dunlop, B. W., Rothbaum, B. O., & Howell, L. L. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4684-8 · Cited by 108
Self-citationTherapeutic Applications of Classic Hallucinogens
Bogenschutz, M. P., & Ross, S. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_464 · Cited by 107
Efficacy and Enlightenment: LSD Psychotherapy and the Drug Amendments of 1962
Oram, M. (2012) · Journal of the History of Medicine and Allied Sciences · doi:10.1093/jhmas/jrs050 · Cited by 103
MDMA alters emotional processing and facilitates positive social interaction
Wardle, M. C., & de Wit, H. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3570-x · Cited by 96 · cited 1×
“MDMA’s effects on emotional information processing (112, 113).”
BackgroundA New Adjunct to the Treatment of Alcoholism: The Hallucinogenic Drugs
Smith, C. M. (1958) · Quarterly Journal of Studies on Alcohol · doi:10.15288/qjsa.1958.19.406 · Cited by 94
Dreams and Psychedelics: Neurophenomenological Comparison and Therapeutic Implications
Kraehenmann, R. (2017) · Current Neuropharmacology · doi:10.2174/1573413713666170619092629 · Cited by 92
Kuypers, K. P., Dolder, P. C., Ramaekers, J. G., & Liechti, M. E. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117699617 · Cited by 89 · cited 1×
“MDMA Serotonin 5-HT2A agonist; mixed serotonin, norepinephrine, and dopamine reuptake inhibition and release Deficits in spatial memory (111); mild impairment on psychomotor tasks (92) Changes in body perception, slight visual and auditory alterations, no hallucinations (92) Distrust and hostility (103); anxiety (93,…”
BackgroundHigh dose psilocybin is associated with positive subjective effects in healthy volunteers
Nicholas, C. R. N., Henriquez, K. M., Gassman, M., Cooper, K. M., Muller, D., Hetzel, S., Brown, R., Cozzi, N. V., Thomas, C., & Hutson, P. R. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118780713 · Cited by 88
Progress and promise for the MDMA drug development program
Feduccia, A. A., Holland, J. A., & Mithoefer, M. C. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4779-2 · Cited by 85
Baggott, M. J., Coyle, J. R., Siegrist, J. D., Garrison, K. J., Galloway, G. P., & Mendelson, J. E. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881115626348 · Cited by 79
MDMA effects consistent across laboratories
Kirkpatrick, M. G., Baggott, M. J., Mendelson, J. E., Galloway, G. P., Liechti, M. E., Hysek, C. M., & de Wit, H. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3528-z · Cited by 78
Carbonaro, T. M., Eshleman, A. J., Forster, M. J., Cheng, K., Rice, K. C., & Gatch, M. B. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3658-3 · Cited by 76
The Potential Dangers of Using MDMA for Psychotherapy
Parrott, A. C. (2014) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2014.873690 · Cited by 75
LSD: My Problem Child—Reflections on Sacred Drugs, Mysticism, and Science
Goodwin, D. W. (1983) · JAMA · doi:10.1001/jama.1983.03340220075044 · Cited by 73
Positive psychology in the investigation of psychedelics and entactogens: a critical review
Jungaberle, H., Thal, S., Zeuch, A., Rougemont-Bücking, A., von Heyden, M., Aicher, H., & Scheidegger, M. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.06.034 · Cited by 70
Hysek, C. M., & Liechti, M. E. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2761-6 · Cited by 67
Kuypers, K. P. C., & Ramaekers, J. G. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0321-7 · Cited by 64
Pharmacology of MDMA- and Amphetamine-Like New Psychoactive Substances
Simmler, L. D., & Liechti, M. E. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_113 · Cited by 59
Liester, M. B. (2015) · Current Drug Abuse Reviews · doi:10.2174/1874473708666150107120522 · Cited by 46
Psychedelic medicine: new evidence for hallucinogenic substances as treatments
(2008) · Choice Reviews Online · doi:10.5860/choice.45-2642 · Cited by 44
Studies with psychedelic drugs in human volunteers
Sellers, E. M., Romach, M. K., & Leiderman, D. B. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.029 · Cited by 42 · cited 3×
“Derealizationmay occur in individuals usingMDMA, but unlike the classic psychedelic compounds, hallucinations are rare (119).”
BackgroundThe wondrous mushroom — Mycolatry in Mesoamerica
Schultes, R. E. (1981) · Journal of Ethnopharmacology · doi:10.1016/0378-8741(81)90041-6 · Cited by 37
Ingram, R., Kang, H., Lightman, S., Jane, D. E., Bortolotto, Z. A., Collingridge, G. L., Lodge, D., & Volianskis, A. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.06.008 · Cited by 36
Novel psychotherapeutics – a cautiously optimistic focus on Hallucinogens
Sherwood, A. M., & Prisinzano, T. E. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1415755 · Cited by 35
Effects of ecstasy on cooperative behaviour and perception of trustworthiness: A naturalistic study
Stewart, L. H., Ferguson, B., Morgan, C. J. A., Swaboda, N., Jones, L., Fenton, R., Wall, M. B., & Curran, H. V. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114544775 · Cited by 34
Buchborn, T., Schröder, H., Dieterich, D. C., Grecksch, G., & Höllt, V. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.12.014 · Cited by 31
Dr. Leary's Concord Prison Experiment: A 34-Year Follow-up Study
Doblin, R. (1998) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1998.10399715 · Cited by 29
Sanacora, G. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18091061 · Cited by 28
Hallucinogen Persisting Perception Disorder and Risk of Suicide
Brodrick, J. E., & Mitchell, B. G. (2015) · Journal of Pharmacy Practice · doi:10.1177/0897190014566314 · Cited by 23
Measure of Significance of Holotropic Breathwork in the Development of Self-Awareness
Miller, T., & Nielsen, L. (2015) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2014.0297 · Cited by 20
(2007) · Choice Reviews Online · doi:10.5860/choice.44-2966 · Cited by 16
Research works printed but not linked: 13
- Lee M, 1992, Acid Dreams: The Complete History of LSD: The CIA, The Sixties, and Beyond
- Darling DC, 2006, Sacred Mushroom of Visions: Teonanácatl: A Sourcebook on the Psilocybin Mushroom
- Pahnke WN, 1969, Int Psychiatry Clin, 5, 149
- Abramson HA: The Use of LSD in Psychotherapy, in Transactions of a Conference on d-Lysergic Acid Diethylamine (LSD-25). New York: Josiah Macy Jr. Foundation Publications, 1959
- Grof S, 1977, The Human Encounter With Death
- Labate BC, 2009, Ayahuasca Religions: A Comprehensive Bibliography and Critical Essays
- Holland J, 2001, Ecstasy: The Complete Guide
- Mithoefer MC, 2013, A Manual for MDMA-Assisted Psychotherapy in the Treatment of Posttraumatic Stress Disorder
- Grof S, 2008, LSD Psychotherapy
- Kalant H, 2001, CMAJ, 165, 917
- Preller KH, 2018, Behavioral Neurobiology of Psychedelic Drugs, 221
- Aarde SM, 2017, Neuropharmacology of New Psychoactive Substances (NPS): The Science Behind the Headlines, 145
- Heifets BD, JAMA Psychiatry
Cited by
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Self-citationThe Critical Relationship Between Anxiety and Depression
Kalin, N. H. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20030305 · Cited by 702
“Also included in this issue is a review of the data addressing the reemergence of the use of psychedelic drugs in psychiatry, particularly for the treatment of depression, anxiety, and PTSD (23).”
BackgroundSelf-citationGukasyan, N., Davis, A. K., Barrett, F. S., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., & Griffiths, R. R. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211073759 · Cited by 425
“, 2018), there remains concern for its potential to cause harm or encourage substance misuse in vulnerable populations (Reiff et al., 2020; Schatzberg, 2020).”
BackgroundTowards an understanding of psychedelic-induced neuroplasticity
Calder, A. E., & Hasler, G. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01389-z · Cited by 313
“Classic psychedelics have been shown to catalyze relatively long-lasting improvements in mental health after a small number of doses, especially when combined with psychotherapy [2].”
BackgroundStructure-based discovery of nonhallucinogenic psychedelic analogs
Cao, D., Yu, J., Wang, H., Luo, Z., Liu, X., He, L., Qi, J., Fan, L., Tang, L., Chen, Z., et al. (2022) · Science · doi:10.1126/science.abl8615 · Cited by 312
Metadata
- Authors
- Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., Kalin, N. H., McDonald, W. M., & and the Work Group on Biomarkers and Novel Treatments, A. D. O. T. A. P. A. C. O. R.
- Affiliations
- Emory University (US)
- Department of Psychiatry, New York University School of Medicine, New York (Reiff); Department of Psychiatry and Human Behavior, Emory University School of Medicine, Atlanta (Richman, McDonald); Department of Psychiatry, Dell Medical School and the Institute for Early Life Adversity Research, University of Texas at Austin (Nemeroff); Department of Psychiatry and Human Behavior, Butler Hospital, Brown University, Providence, R.I. (Carpenter); Department of Psychiatry and Behavioral Sciences, University of...
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2020-05-01
- Volume
- 177
- Issue
- 5
- Pages
- 391-410
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W3006905788
- Cited by
- 649
- References
- 120
- Citations by year
- 2026: 93 · 2025: 126 · 2024: 129 · 2023: 113 · 2022: 102 · 2021: 60 · 2020: 26
- FWCI
- 5.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (P30AG059307)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Keywords
- psychedelics, psychedelic-assisted psychotherapy, psilocybin, LSD, ayahuasca, MDMA, post-traumatic stress disorder, treatment-resistant depression, cancer-related anxiety, substance use disorders, trauma and stress-related disorders, end-of-life care
- MeSH terms
- Mental Disorders, Hallucinogens, Humans, Lysergic Acid Diethylamide, Psilocybin, Psychotherapy, N-Methyl-3,4-methylenedioxyamphetamine, Evidence-Based Practice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.